Telitacicept shows kidney function benefit in two-year IgA nephropathy trial

October 22, 2026 4:05 PM

Vor Bio (NASDAQ: VOR) announced two-year results from the Phase 3 TELIGAN trial evaluating telitacicept in adults with IgA nephropathy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found